I think our ability to stay on the playing field will eventually allow us to overcome any checkered past because our products, regardless of any blunders GC may have made, all speak for themselves. As for GC blundering, put ANY highly decorated CEO in the same position here on the otc with start up biotech looking to take it from pre clinical study allll the way to market...will blunder and blunder big. Moving forward, it's what that or any CEO does to correct past blunders and ability to stay on the playing field is what the market will notice going forward. That in itself will attract any and everything we will need...upfront $$$ milestone payments, buyouts, partnerships etc etc, basically the same opportunities/situations we've needed for the past 5 years. Nice going GC by keeping company doors open and lights on.
(10)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links